Publications
115
Citations
2,403
Est. group size
~28
Recurring co-author estimate
Active years
15
Publishing since 2012
Alexa Meara's research focuses on rheumatic complications that arise from cancer immunotherapy, particularly immune checkpoint inhibitors, which are drugs that help the immune system attack tumors but can also cause it to attack healthy tissue. Her work spans clinical guidelines, patient education tools, and shared decision-making resources for conditions like inflammatory arthritis and lupus that intersect with cancer treatment. This research is relevant to students interested in rheumatology, oncology, and improving how patients and doctors make treatment decisions together.
Publication output has grown substantially over the past decade, rising from about 5-8 papers per year in 2017-2022 to over 20 per year in 2023-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- PS5-06-09: Immunotherapy induced Kikuchi Fujimoto (Histiocytic Necrotizing Lymphadenitis): A Rare Immune Related Adverse Event
Clinical Cancer Research · 2026
- Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
Annals of the Rheumatic Diseases · 2026
- Immunotherapy Complications
Emergency Medicine Clinics of North America · 2025
- Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer · 2025
- Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation study
The Lancet Rheumatology · 2025
- Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics
Lara D. Veeken · 2025
- A Case of Steroid‐Dependent Immune Checkpoint Inhibitor Pneumonitis Treated With Subcutaneous Tocilizumab
Respirology Case Reports · 2025
- Expert Clinical Management of Inflammatory Immune-Related Arthritis in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Journal of Immunotherapy and Precision Oncology · 2025
- POS1234 ORAL GLUCOCORTICOID TREATMENT FOR CHECKPOINT INHIBITOR ASSOCIATED INFLAMMATORY ARTHRITIS DO NOT AFFECT PROGRESSION FREE SURVIVAL: A RADIOS REGISTRY COHORT STUDY [DJK1]THE 5000 CHARACTERS FOR REGULAR SUBMISSIONS
Annals of the Rheumatic Diseases · 2025
- 1062 Understanding educational needs and barriers in immune-related adverse event management: an ASPIRE initiative
Regular and Young Investigator Award Abstracts · 2025
- Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets
Seminars in Arthritis and Rheumatism · 2024
- Acknowledging and addressing real-world challenges to treating immune-related adverse events
Journal for ImmunoTherapy of Cancer · 2024
- The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis
Rheumatic Disease Clinics of North America · 2024
- Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials
Seminars in Arthritis and Rheumatism · 2024
- Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events
Journal of Clinical Oncology · 2024
- Seminars in Arthritis and Rheumatism×7
- Journal of Clinical Oncology×7
- Annals of the Rheumatic Diseases×7
- The Journal of Rheumatology×5
- Rheumatic Disease Clinics of North America×5
- Andreas Wieland
Medicine · The Ohio State University
- Abdul Miah
Medicine · The Ohio State University
- Adam Khorasanchi
Medicine · The Ohio State University
- Amir Yousif
Medicine · The Ohio State University
- Andrew J. Gunderson
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile